FGF8b, Human

FGF8b, Human

Two of the four human FGF8 splice isoforms, FGF8a and FGF8b, are expressed in the mid-hindbrain region during development. Although the only difference between these isoforms is the presence of an additional 11 amino acids at the N terminus of FGF8b, these isoforms possess remarkably different abilities to pattern the midbrain and anterior hindbrain.
Z05294
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
FGF8b (Gln23-Arg215)
Accession # P55075-3
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 0.01EU per μg by the LAL method.
Biological Activity Measured in a cell proliferation assay using Balb/c 3T3 mouse fibroblasts. The ED50 for this effect is 5­20 ng/mL. Test result was comparable to standard batch
Expression System E.coli
Theoretical Molecular Weight 22.39 kDa
Apparent Molecular Weight The protein has a predicted MW of 22.39 kDa same as Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in 20mM Tris, 300mM NaCl (pH 8.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Two of the four human FGF8 splice isoforms, FGF8a and FGF8b, are expressed in the mid-hindbrain region during development. Although the only difference between these isoforms is the presence of an additional 11 amino acids at the N terminus of FGF8b, these isoforms possess remarkably different abilities to pattern the midbrain and anterior hindbrain.
Synonyms FGF8b; FGF-8b; FGF-8; FGF8; FGF 8; AIGF; HBGF-8; HBGF8; HBGF 8;

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.